1
|
Al-Ansari
2010
Qatar
|
Tamsulosin 0.4mg
|
Placebo
|
4 weeks
|
37.1(9.4)/36.1(9.3)
|
32,18/35,15
|
Yes
|
5.8(2.4)/6(2.5)
|
2
|
Aldemir
2010
Turkey
|
Group I- Tamsulosin 0.4mg
Group II- Rowatinex 100mg thrice daily
|
Diclofenac 100 mg
|
10 days
|
42.4(16)/46.5(1.6.5)/43.5(16.6)
|
22,9/17,13/19,10
|
Yes
|
6.7(1.4)/6.8(2)/6.6(1.7)
|
3
|
Alizadeh
2014
Iran
|
Tamsulosin 0.4 mg
|
No treatment
|
4 weeks
|
-
|
29,21/32,14
|
3-6 mm
|
-
|
4
|
Bajwa
2013
Pakistan
|
Tamsulosin 0.4 mg
|
Diclofenac 50 mg
|
4 weeks
|
32.4(8.3)/33.8(9.6)
|
18,12/19,11
|
Yes
|
6.9(1.4)/6.6(1.4)
|
5
|
Cervenakov
2002
Slovakia
|
Tamsulosin 0.4 mg
|
Tramadol 50 mg
Diazepan and Veral 50
|
-
|
-
|
32,19/33,18
|
Yes
|
-
|
6
|
ElGamal
2011
Egypt
|
Group II Tamsulosin 0.4mg
|
Group I Placebo control
Group III Uralyt-U
Group IV Uralyt-U plus tamsulosin
|
4 weeks
|
(Tamsulosin and placebo)
35.3(5.7)/36.2(6)
|
(Tamsulosin and placebo)
32,16/34,12
|
Yes
|
(Tamsulosin and placebo)
7.9(1.9)/7.7(1.6)
|
7
|
ElGalaly
2015
Egypt
|
Group I Tamsulosin 0.4 mg
Group II Silodosin 8mg
|
-
|
4 weeks
|
Tamsulosin/Silodosin
35.5(11)/33.6(9.9)
|
Tamsulosin/Silodosin
(32,19/35,17)
|
Yes
|
Tamsulosin/Silodosin
(5.6(1.2)/5.4(1.5)
|
8
|
Vincendeau
2010
France
|
Tamsulosin 0.4 mg
|
Placebo
|
6 weeks
|
38.9(12)/39(11)
|
43,18/52,9
|
2-7 mm
|
2.9(1)/3.2(1.2)
|
9
|
Yilmaz
2004
Turkey
|
Group II Tamsulosin 0.4mg
Group III Terazosin 5mg
Group IV Doxazosin 4mg
|
Group I No treatment
|
4 weeks
|
(Tamsulosin/control)
40.6(10),41.6(12)
|
(Tamsulosin/control)
9,20/19,9
|
Yes
|
(Tamsulosin/control)
6(1.2)/6(1.4)
|
10
|
Aggarwal
2009
India
|
I - Tamsulosin
II – Alfuzosin
|
III -
Placeo
|
4 weeks
|
I(31.4 yrs)
II(38.7 yrs)
III(35.3 yrs)
|
I(26/8)
II(28/6)
III(24/10)
|
Yes
|
I(6.17 mm)
II(6.7mm)
III(6.35 mm)
|
11
|
Ahmad
2015
Pakistan
|
I -Tamsulosin
|
II- Placebo
|
4 weeks
|
NA
|
4-10mm
|
<8mm
|
5.78mm
|
12
|
Cha
2012
Korea
|
I(Tamsulosin-0.2mg OD)
II(Tamsulosin - 0.2 mg BD)
III(Alfuzosin)
IV(Trospium)
|
-
|
4 weeks
|
I(45.07 yrs)
II(45.5 )
III(42.33 )
IV(43.65
|
I(31/10)
II(20/10)
III(25/11)
IV(18/16)
|
4-10mm
|
I(5.49mm)
II(5.73mm)
III(5.81mm)
IV(5.59mm)
|
13
|
Dell’atti
2015
Italy
|
I-Tamsulosin
II- Silodosin
|
-
|
3 weeks
|
I(35 yrs)
II(36 yrs)
|
I(39/27)
II(44/23)
|
4-10mm
|
I( 5.37mm)
II(5.82mm)
|
14
|
Furyk
2015
Australia
|
I -Tamsulosin
|
II-Placebo
|
4 weeks
|
> 18 yrs
|
I(156/42)
II(164/31
|
Yes
|
I(4mm)
II(3.7mm)
|
15
|
Gomez
2011
Mexico
|
I- Tamsulosin
|
II-Placebo
|
4 weeks
|
I(38.5 yrs)
II(38.2 yrs)
|
I(15/17)
II(21/12)
|
5-10mm
|
I(5.3mm)
II(5.2mm)
|
16
|
Hermanns
2009
Switzerland
|
I-Tamsulosin
|
II-Placebo
|
3 weeks
|
I(36 yrs)
II(41 yrs)
|
I(39/6)
II(36/9)
|
7mm or less
|
I(4.1mm)
II(3.8mm)
|
17
|
Itoh
2013
Japan
|
II- Silodosin
|
I -Placebo
|
4 weeks
|
I(55.8 yrs)
II(56.3 yrs)
|
all male
|
Yes
|
I(4.87mm)
II(5.07mm)
|
18
|
Kumar
2015
India
|
I- Tamsulosin
II- Silodosin
III- Tadalafil
|
-
|
4 weeks
|
I(36.4 yrs)
II(36.7 yrs)
III(37.5 yrs)
|
I(62/28)
II(64/26)
III(67/23)
|
5-10mm
|
I(7.44mm)
II(7.5mm)
III(7.7mm)
|
19
|
Sameer
2014
India
|
I-Nifedipine
II- Alfuzosin
|
III- Control
|
4 weeks
|
I(32.74 yrs)
II(30.82 yrs)
III(33.06 yrs)
|
I(19/16)
II(26/9)
III(23/12)
|
Yes
|
I(6.5mm)
II(6.28mm)
III(6.37mm)
|
20
|
Ahmad
2010
Saudi Arabia
|
I- Tamsulosin 0.4mg
II- Alfuzosin 10mg
|
III- control- Diclofenac 75mg
|
30 days
|
I/II/III- 40.7(14.8)/41.1(15.2)/38.9(13.3)
|
I/II/III- 19,10/18,12/19,09
|
Yes
|
I/II/III- 4.97(2.24)/5.47(2.13)/5.39(1.81)
|
21
|
Elsaid
2015
Egypt
|
Alfuzosin 5mg BD
|
control -Diclofenac + Hydration
|
4 weeks
|
Alfuzosin/Control- 32.8(9.5)/ 32.1(9.2)
|
Alfuzosin/control- 18,10/16,10
|
Yes
|
Alfuzosin/Control- 6.3(2.1)/5.9(1.9)
|
22
|
Nuraj
2017
Kosovo
|
I-Tamsulosin 0.4mg
|
Control- Diclofenac
|
4 weeks
|
Tamsulosin/Control35.5(11.0)/35.4(10.8)
|
Tamsulosin/Control34,18/35,17
|
4-10mm
|
Tamsulosin/Control
6.5(1.6)/6.6(1.5)
|
23
|
Pedro
2008
USA
|
I- Alfuzosin
|
Placebo
|
4 weeks
|
Alfuzosin/Placebo
36.69(13.66)/ 42.03(12.85)
|
Alfuzosin/Placebo
28,6/27,8
|
Up to 8mm
|
Alfuzosin/Placebo- 3.83(0.94)/4.07(1.13)
|
24
|
Pickard
2015
UK
|
I- Tamsulosin 0.4mg
II- Nifedipine 30 mg
|
III- Placebo
|
4 weeks
|
I/II/III- 43.1(11.5)/42.3(11.0)/48.2(12.3)
|
I/II/III- 315,68/317,66/299,85
|
Yes
|
I/II/III- 4.6(1.6)/ 4.5(1.6)/4.5(1.7)
|
25
|
Rahman
2017
India
|
I-Tamsulosin 0.4mg OD
II- Silodosin 8 mg OD
III- Silodosin 8mg + Tadalafil 5 mg
|
|
4 weeks
|
I/II/III- 38(10)/34(12)/ 35(10)
|
I/II/III- 24,16/22,18/25,15
|
5-10mm
|
I/II/III- 7.5(1.20)/7.4(1.30)/7.6(1.35)
|
26
|
Sur
2015
USA
|
I- Silodosin 8mg OD
|
II- Placebo
|
4 weeks
|
I/II-
47(13)/47(15)
|
I/II- 72,53/80,37
|
4-10mm
|
I/II- 5.4(1.4)/5.5(1.6)
|
27
|
Wang
2008
Taiwan
|
I- Tamsulosin 0.4 mg OD
II- Terazosin 2 mg OD
|
III- control
|
2 weeks
|
Tamsulosin/Terazosin/Control- 50.4(9.7)/ 51.4(8.6)/50.9(9.6)
|
I/II/III- 22,10/21,11/23,08
|
Yes
|
I/II/III-
6.5(1.3)/6.5(1.5)/6.5(1.4)
|
28
|
Ye
2017
Wuhan, China
|
I- Tamsulosin
0.4mg
|
II- Placebo
|
4 weeks
|
I/II
40.1(11.6)/40.7(12.3)
|
I/II-
556,1086/605,1049
|
Yes
|
I/II-
5.8(1.9)/5.7(1.8)
|
29
|
Sio
2006
Italy
|
I- Diclofenac 100mg/day + Aescin 80mg/day
II- Diclofenac 100mg + Aescin 80mg + Tamsulosin 0.4 mg
|
|
2 weeks
|
I/II- 44.5(11.3)/46.3(10.9)
|
I/II
26,20/36,14
|
Yes
|
I/II
6.4(1.3)/6.9(1.0)
|
30
|
Wang
2015
Taiwan
|
I- Silodosin 8mg
|
II- control
|
2 weeks
|
51.4(8.6)/51.5(10.5)
|
40,22/43,18
|
Yes
|
6.4(1.4)/6.4(1.3)
|
31
|
Yuksel
2015
Turkey
|
Group II Silodosin 4 mg/day
|
Group I Placebo
|
3 weeks
|
Placebo/Silodosin
35.23(11.20) /35.31(11.55)
|
gp I /gp II
20,15/19,16
|
4-10mm
|
6.34(1.57)/ 6.40(1.61)
|
32
|
Porpiglia
2004
Italy
|
Group I- Nifedipine 30 mg + Deflazacort 30 mg x 10 days + Mysoprostol
200ug
Group II- Tamsulosin 0.4 mg + Deflazacort 30 mg x 10 days + Mysoprostol
200ug
|
Group III- no expulsive therapy given
|
4 weeks
|
Group I/II/III-
45.6 (12)/
50.5(17)/
42.7 (16)
|
I/II/III-
19,11/
18,10/
16,12
|
<= 1 cm
Yes
|
I/II/III-
4.7 (1.47)/
5.42(1.54)/
5.35 (1.49)
|
33
|
DellaBella
2005
Italy
|
Group I- Phloroglucinol 80 mg 3 tabs OD
Group II- Tamsulosin 0.4 mg OD
Group III- Nifedipine SR 30 mg OD
|
Tab Cotrimoxazole 2 tabs OD x 8 days
Tab. Deflazacort 30 mg OD x 10 days in each group
|
4 weeks
|
Group I/II/III
39.8 (12.7)/
43.8 (13.9)/
41.8( 15.4)
|
I/II/III-
50/20,
54/16, 51/19
|
>4mm
|
I/II/III-
6.2 (1.7),
7.2 (2.4),
6.2 (1.5)
|
34
|
Ye
2011
China
|
Tamsulosin and nifedipine 3o mg
|
-
|
4 weeks
|
30.7(18-48)/34.5(22-50)
|
998,598/989,604
|
|
|
35
|
Balci
2014
Turkey
|
Tamsulosin and nifedipine 3o mg
|
|
4 weeks
|
39.5(12)/36.4(11.5)
|
18,7/17,8
|
|
7(1.5)/6.4(1)
|
36
|
Gandhi
2013
Nepal
|
Tamsulosin and nifedipine 3o mg
|
-
|
4 weeks
|
34(12.8)/30.4(11)
|
38,26/36,28
|
|
8.6(2.3)/8.9(2.5)
|
37
|
Shokeir
2016
Egypt
|
II-Sildenafil
|
I-Placebo
|
4 Weeks
|
45.3 yrs
45.8yrs
|
NA
|
Yes
|
NA
|
38
|
Zhang
2009
China
|
Tamsulosin and nifedipine 3o mg
|
-
|
4 weeks
|
34.6(11.4)/36.3(9.7)
|
63,29/68,29
|
Yes
|
6.9(1.6)/6.8(1.6)
|
39
|
Islam
Bangladesh
|
Tamsulosin and nifedipine 2o mg
|
-
|
4 weeks
|
46.6/47.4
|
20,12/21,10
|
|
5.9(3-10)/6(3.5-10)
|
40
|
Lv
2014
China
|
Group I - Naftopidil 50mg/day
Group II- Naftopidil 50 mg/day + Celecoxib 200mg BD
|
Group III -Celecoxib
200 mg BD
|
2 weeks
|
Group I/II/III
31.40 ± 3.94/ 33.20 ± 5.28/ 33.75 ± 5.24
|
Group I/II/III
20/15, 21/14,
18/15
|
4-9mm
|
I/II/III-
6.9 ± 1.30 /
7.1 ± 1.50/
7.3 ± 1.2
|
41
|
Sun
2008
China
|
Group II- Naftopidil 50 mg OD
|
Group I - control
No MET given
|
2 weeks
|
Group I/II- Control/ Naftopidil
37.8( 10.2)/
38.2 (12.6)
|
Control/Naftopidil-
24/6 ,
26/4
|
-
|
Control/ Naftopidil-
5.7 (1.2) /
5.5 (1.2)
|
42
|
Zhou
2011
China
|
Group I- Naftopidil 10 mg OD
Group II- Tamsulosin 0.4 mg OD
|
Group III- control
no MET
|
2 weeks
|
group I/II/III-
33.73 ± 8.84/ 34.42 ± 8.64/
34.79 ± 9.63
|
Group I/II/III-
25/18. 27/18, 27/16
|
Yes
4-9 mm
|
Group I/II/III-
6.67 ± 0.81 6.54 ± 0.57 6.61 ± 0.74
|
43
|
Kumar
2013
India
|
I Naftopidil
II tamsulosin Prednisolone given to both groups
|
III control
|
4 weeks
|
33.2/33.2/33.5
|
-
|
6.9/7.1/6.6
|
5-10 mm
|
44
|
Kumar
2014
India
|
I-Tamsulosin
II-Tamsulosin +Tadalafil
|
Prednisolone given to both groups
|
6 Weeks
|
I(32.45 yrs)
II(35.23 yrs)
|
I(19/12)
II(25/6)
|
Yes
|
I(7.05mm)
II(6.67mm)
|
45
|
KC
2016
Nepal
|
I-Tamsulosin
II- Tadalafil
|
NA
|
2 Weeks
|
I(31.37 yrs)
II(32.05 yrs)
|
I(27/14)
II(24/20)
|
Yes
|
I(7.09mm)
II(7.13mm)
|
46
|
Puvvada
2016
India
|
I-Tadalafil
II-Tamsulosin
|
NA
|
4 Weeks
|
I(36.34 yrs)
II(37.53 yrs)
|
I(65/35)
II(67/33)
|
Yes
|
I(7.10mm)
II(7.22mm)
|
47
|
Jayant
2014
India
|
I-Tamsulosin
II- Tamsulosin+Tadalafil
|
NA
|
4 weeks
|
I(36.45 yrs)
II(37.23 yrs)
|
I(65/57)
II(67/55)
|
Yes
|
I(6.72mm)
II(7.05mm)
|
48
|
Porpiglia
2000
Italy
|
Group A: Deflazacort 30mg for 10 days and Nifedipine 30 mg
|
Group b: no treatment
|
4 weeks
|
-
|
26,22/24,24
|
5.8(18)/5.5(1.4)
|
< 10mm
|
49
|
Shabana
2016
Egypt
|
Group A: Tamsulosin
Group B: Tamsulosin plus methylprednisolone
Group C: Alfuzosin
Group D: Alfuzosin plus methylprednisolone
|
-
|
2 weeks
|
53/51/49/49
|
30,23/29,24/31,22/27,26
|
7.8/8.1/7.9/8
|
Yes
|
50
|
Borghi
1994
Italy
|
Nifedipine plus methylprednisolone
|
Placebo
|
45 days
|
-
|
-
|
6.7/6.8
|
Yes
|